<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00609362</url>
  </required_header>
  <id_info>
    <org_study_id>2007-223</org_study_id>
    <nct_id>NCT00609362</nct_id>
  </id_info>
  <brief_title>The Effect of Glitazone Treatment on Bone Marrow and Bone Marrow Cells</brief_title>
  <official_title>The Effect of Glitazone Treatment on Bone Marrow and Bone Marrow Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoporosis is a generalised bone disease leading to an increased risk of fractures. The
      disease is caused partly by environmental and partly by genetic factors. It is well known
      that the fat content of the bone marrow is increased in osteoporotic patients. Animal studies
      suggest that stimulation of bone marrow stem cells through the molecule PPARgamma with the
      drug rosiglitazone converts the stem cells to fat cells instead of bone cells thereby
      decreasing bone strength. In a single study healthy volunteers were treated with
      rosiglitazone for 14 weeks and had a decrease in bone mineral density.

      In the present study we wish to investigate the effect of this treatment on bone and fat
      tissue. 25 women above the age of 60 will be treated with rosiglitazone 8 mg/day for 14 weeks
      and compared with 25 women receiving placebo.

      The effect will be evaluated as follows:

        1. The effect on bone marrow density will be examined by a bone scan prior to and after
           treatment and again after 6 and 9 months.

        2. The effect on bone turnover will be measured in blood- and urine samples at the same
           times.

        3. The effect on fat distribution will be evaluated by an MRI scan after treatment.

        4. The effect on bone marrow cells will be investigated bone marrow sampling immediately
           after treatment

        5. The direct effect on fat will be examined by a biopsy immediately after treatment The
           study hypothesis is that rosiglitazone treatment decreases bone mineral density and
           increases bone marrow fat content. The causal molecular mechanisms will be investigated
           from the bone marrow and fat samples
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Percent Change in Bone Mineral Density (BMD) From Baseline to 14 Weeks Between the Rosiglitazone Group and the Placebo Group</measure>
    <time_frame>BMD measured at baseline and after 14 weeks of treatment</time_frame>
    <description>Difference in percent change in bone mineral density (BMD) from baseline to 14 weeks between the rosiglitazone group and the placebo group. BMD was assesed using dual x-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Percent Change in Bone Marrow Fat (Given by a Lipid to Water Ratio) in the Spine.</measure>
    <time_frame>Measured at baseline and after 14 weeks of treatment</time_frame>
    <description>Bone marrow fat was measured using MRI spectroscopy providing a measure of bone marrow fat as a ratio to bone marrow water, the lipid-water ratio (LWR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Percent Change in Level of C-terminal Telopeptide (CTx) Between the Rosiglitazone and Placebo Groups</measure>
    <time_frame>At baseline and after 14 weeks of treatment</time_frame>
    <description>C-terminal telopeptide is a marker of bone resorption. Its levels are measure in plasma using a chemiluminometric method (ECLIA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gene Expression in Bone Marrow and Fat Cells</measure>
    <time_frame>Before and after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Change in Bone Mineral Density</condition>
  <condition>Change in Bone Marrow Fat Content</condition>
  <arm_group>
    <arm_group_label>Rosiglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 women age 60 to 75 years receiving rosiglitazone 8 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>25 women 60 to 75 years of age receiving placebo once a day for 14 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
    <description>one tablet of rosiglitazone 8 milligrams per day for 14 weeks</description>
    <arm_group_label>Rosiglitazone</arm_group_label>
    <other_name>Avandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <description>One encapsulated placebo pill a day for 14 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women age 60-75 with no rosiglitazone allergy

        Exclusion Criteria:

          -  Osteoporosis

          -  Diabetes

          -  Hyperthyroidism, untreated hypothyroidism, hyperparathyroidism

          -  Treatment with bone active drugs

          -  Low impact fracture

          -  Heart disease

          -  Kidney failure

          -  Liver failure

          -  Anaemia

          -  Ineligibility for MRI-scan

          -  Cancer within last 5 years
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torben Harsl√∏f, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000 C</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2008</study_first_posted>
  <results_first_submitted>February 17, 2011</results_first_submitted>
  <results_first_submitted_qc>March 29, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 27, 2011</results_first_posted>
  <last_update_submitted>March 29, 2011</last_update_submitted>
  <last_update_submitted_qc>March 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Bente Langdahl</name_title>
    <organization>Aarhus University Hospital</organization>
  </responsible_party>
  <keyword>BMD</keyword>
  <keyword>Rosiglitazone</keyword>
  <keyword>Bone marrow fat</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment commenced january 2008 and ended february 2009. Participants were recruited by ads in local papers and called our osteoporosis clinic. 179 called and after a course description 150 were sent information. After having read that 74 paid a visit to the clinic.</recruitment_details>
      <pre_assignment_details>74 individuals were screened. 17 were screen failures due to exclusion criteria. 57 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rosiglitazone</title>
          <description>25 women age 60 to 75 years receiving rosiglitazone 8 mg/day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>25 women 60 to 75 years of age receiving placebo once a day for 14 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rosiglitazone</title>
          <description>25 women age 60 to 75 years receiving rosiglitazone 8 mg/day</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>25 women 60 to 75 years of age receiving placebo once a day for 14 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.1" spread="3.5"/>
                    <measurement group_id="B2" value="65.3" spread="4.3"/>
                    <measurement group_id="B3" value="65.2" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in Percent Change in Bone Mineral Density (BMD) From Baseline to 14 Weeks Between the Rosiglitazone Group and the Placebo Group</title>
        <description>Difference in percent change in bone mineral density (BMD) from baseline to 14 weeks between the rosiglitazone group and the placebo group. BMD was assesed using dual x-ray absorptiometry (DXA)</description>
        <time_frame>BMD measured at baseline and after 14 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>25 women age 60 to 75 years receiving rosiglitazone 8 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>25 women 60 to 75 years of age receiving placebo once a day for 14 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Percent Change in Bone Mineral Density (BMD) From Baseline to 14 Weeks Between the Rosiglitazone Group and the Placebo Group</title>
          <description>Difference in percent change in bone mineral density (BMD) from baseline to 14 weeks between the rosiglitazone group and the placebo group. BMD was assesed using dual x-ray absorptiometry (DXA)</description>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="3.1"/>
                    <measurement group_id="O2" value="0.3" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The minimum number of participants was determined by power calculations to be 44 (22 in each group), assuming a difference in change in BMD of 1.7%, a standard deviation of 2%, a power of 80%, and a level of significance of 5%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.055</p_value>
            <p_value_desc>P-value is un-adjusted. A priori threshold for significance: 0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Percent Change in Bone Marrow Fat (Given by a Lipid to Water Ratio) in the Spine.</title>
        <description>Bone marrow fat was measured using MRI spectroscopy providing a measure of bone marrow fat as a ratio to bone marrow water, the lipid-water ratio (LWR)</description>
        <time_frame>Measured at baseline and after 14 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>25 women age 60 to 75 years receiving rosiglitazone 8 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>25 women 60 to 75 years of age receiving placebo once a day for 14 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Percent Change in Bone Marrow Fat (Given by a Lipid to Water Ratio) in the Spine.</title>
          <description>Bone marrow fat was measured using MRI spectroscopy providing a measure of bone marrow fat as a ratio to bone marrow water, the lipid-water ratio (LWR)</description>
          <units>Percent change in LWR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.5" spread="5.5"/>
                    <measurement group_id="O2" value="6.8" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Percent Change in Level of C-terminal Telopeptide (CTx) Between the Rosiglitazone and Placebo Groups</title>
        <description>C-terminal telopeptide is a marker of bone resorption. Its levels are measure in plasma using a chemiluminometric method (ECLIA).</description>
        <time_frame>At baseline and after 14 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>25 women age 60 to 75 years receiving rosiglitazone 8 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>25 women 60 to 75 years of age receiving placebo once a day for 14 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Percent Change in Level of C-terminal Telopeptide (CTx) Between the Rosiglitazone and Placebo Groups</title>
          <description>C-terminal telopeptide is a marker of bone resorption. Its levels are measure in plasma using a chemiluminometric method (ECLIA).</description>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4" spread="38.6"/>
                    <measurement group_id="O2" value="-7.1" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Gene Expression in Bone Marrow and Fat Cells</title>
        <time_frame>Before and after treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rosiglitazone</title>
          <description>25 women age 60 to 75 years receiving rosiglitazone 8 mg/day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>25 women 60 to 75 years of age receiving placebo once a day for 14 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Tendinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Torben Harsl√∏f, MD</name_or_title>
      <organization>University of Aarhus</organization>
      <phone>+4589497681</phone>
      <email>torbhars@rm.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

